HCPCS J3385: Injection, velaglucerase alfa, 100 units
HCPCS Level II code J3385 describes an injectable biologic, velaglucerase alfa, supplied in 100-unit increments for enzyme replacement therapy; the service is an infusion/injection medication administration typically provided in hospital outpatient infusion centers, specialty infusion clinics, or physician office settings for treatment of conditions requiring glucocerebrosidase replacement.
For related coverage guidance, see recent payer policy updates: Bendamustine Products Coverage Criteria, T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and Romidepsin, Brentuximab Vedotin (Adcetris®) Coverage Criteria.
Customize your policy alerts
Sign up for hcpcs J3385 policy alerts
Get alerted when payer policies referencing J3385 are released or updated.
Monitor payer policy activity